PT  - JOURNAL ARTICLE
AU  - Katherine M. Jia
AU  - Hallie Eilerts
AU  - Olanrewaju Edun
AU  - Kevin Lam
AU  - Adam Howes
AU  - Matthew L. Thomas
AU  - Jeffrey W. Eaton
TI  - Risk scores for predicting HIV incidence among adult heterosexual populations in sub-Saharan Africa: a systematic review and meta-analysis
AID  - 10.1101/2021.09.28.21264246
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.28.21264246
4099  - http://medrxiv.org/content/early/2021/11/12/2021.09.28.21264246.short
4100  - http://medrxiv.org/content/early/2021/11/12/2021.09.28.21264246.full
AB  - Introduction Several HIV risk scores have been developed to identify individuals for prioritised HIV prevention in sub-Saharan Africa. We systematically reviewed HIV risk scores to: (i) identify factors that consistently predicted incident HIV infection, (ii) review inclusion of community-level HIV risk in predictive models, and (iii) examine predictive performance.Methods We searched nine databases from inception until February 15, 2021 for studies developing and/or validating HIV risk scores among the heterosexual adult population in sub-Saharan Africa. Studies not prospectively observing seroconversion or recruiting only key populations were excluded. Record screening, data extraction, and critical appraisal were conducted in duplicate. We used random-effects meta-analysis to summarise hazard ratios and the area under the receiver-operating characteristic curve (AUC-ROC).Results From 1563 initial search records, we identified 14 risk scores in 13 studies. Seven studies were among sexually active women using contraceptives enrolled in randomised-controlled trials, three among adolescent girls and young women (AGYW), and three among cohorts enrolling both men and women. Consistently identified HIV prognostic factors among women were younger age (pooled adjusted hazard ratio: 1.62 [95% Confidence Interval: 1.17, 2.23], compared to above-25), single/not cohabiting with primary partners (2.33 [1.73, 3.13]) and having sexually transmitted infections (STIs) at baseline (HSV-2: 1.67 [1.34, 2.09]; curable STIs: 1.45 [1.17; 1.79]). Among AGYW only STIs were consistently associated with higher incidence, but studies were limited (n=3). Community-level HIV prevalence or unsuppressed viral load strongly predicted incidence but were only considered in three of 11 multi-site studies. The AUC-ROC ranged from 0.56 to 0.79 on the model development sets. Only the VOICE score was externally validated by multiple studies, with pooled AUC-ROC 0.626 [0.588, 0.663] (I2: 64.02%).Conclusions Younger age, non-cohabiting, and recent STIs were consistently identified as predicting future HIV infection. Both community HIV burden and individual factors should be considered to quantify HIV risk. However, HIV risk scores had only low-to-moderate discriminatory ability and uncertain generalisability, limiting their programmatic utility.Further evidence on the relative value of specific risk factors, studies populations not restricted to ‘at-risk’ individuals, and data outside South Africa will improve the evidence base for risk differentiation in HIV prevention programmes.PROSPERO Number CRD42021236367Competing Interest StatementJWE reports grants from Bill and Melinda Gates Foundation and UNAIDS during the conduct of the study; grants from NIH, UNAIDS, and WHO and personal fees from WHO outside the submitted work. All other authors declare no competing interests.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=236367 Funding StatementThis research was supported by the Bill & Melinda Gates Foundation (Grant numbers: OPP1190661, INV-002606, OPP1164897), UNAIDS, and the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The manuscript is a systematic review and therefore did not require IRB review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript is a systematic review. All extracted data are reported in the supplementary material.AGYWadolescent girls and young women(a)HR(adjusted) hazard-ratioAUC-ROCarea under the receiver operating characteristic curveCHARMSCritical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies ChecklistHSV-2Human Simplex Virus – 2MMCmale medical circumcisionPrEPpre-exposure prophylaxisPROBASTPrediction Model Risk of Bias assessment tool checklistPRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysesRCTrandomised controlled trialSTIsexually transmitted infection